Expanding a Stroke Legacy: Terumo Neuro Announces US Commercial Availability of the SOFIA™ 88 Neurovascular Support Catheter
Rhea-AI Summary
Terumo Neuro (TRUMY) has announced the US commercial launch of its SOFIA™ 88 Neurovascular Support Catheter, expanding its stroke treatment portfolio. The new catheter features an 0.088-inch inner diameter and builds upon the SOFIA™ Catheter line's decade-long legacy of supporting over 500,000 procedures across 170 countries.
The SOFIA™ 88 catheter offers key benefits including reliable trackability through challenging anatomy, proximal stability for procedural ease, and vessel-friendly flexibility. It is compatible with the SOFIA™ Flow Plus 6F Aspiration Catheter and integrates with Terumo's comprehensive stroke solution portfolio, which includes aspiration catheters, retrieval devices, balloon guide catheters, microcatheters, and guidewires.
Positive
- Strong clinical legacy with SOFIA™ Catheter line used in over 500,000 procedures across 170 countries
- Positive physician feedback highlighting improved access and first pass effect
- Expanded product portfolio strengthening company's position in neurovascular market
- Compatible with existing aspiration strategies and complementary products
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, TRUMY declined 0.47%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Terumo Neuro's
Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance, the SOFIA™ 88 Neurovascular Support Catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements designed to provide the following benefits:
- Reach with Confidence – Reliable trackability through challenging anatomy via optimized transition zones and a soft, atraumatic distal tip.
- Support to Go the Distance – Proximal stability for procedural ease with both short and long sheaths.
- Atraumatic by Design – Flexibility and reinforcement throughout the entire working length to minimize vessel trauma and support smooth navigation.
"Terumo Neuro's
"As we introduce the SOFIA™ 88 Neurovascular Support Catheter, we are building on a decade of performance that physicians around the world have come to trust," said Carsten Schroeder, President and CEO of Terumo Neuro. "This launch reflects our continued investment in neurovascular innovation, made possible through direct collaboration with physicians and our strong R&D and manufacturing capabilities. Together, we are delivering meaningful advancements in stroke care designed to improve outcomes for patients worldwide."
The SOFIA™ 88 Neurovascular Support Catheter is compatible with the SOFIA™ Flow Plus 6F Aspiration Catheter and supports integration into existing aspiration strategies. Clinical evidence from the SOFAST registry—evaluating the SOFIA™ Flow Plus 6F as a first-line approach—demonstrated strong results across speed, efficacy, and safety and overall clinical outcomes.
The new SOFIA™ 88 Catheter also seamlessly complements the company's broader stroke solution portfolio, offering a fully integrated approach across aspiration, access, retrieval, and navigation:
- SOFIA™ and SOFIA™ Flow Plus Aspiration Catheters – Renowned for trackability and clinical performance
- ERIC™ Retrieval Device – Designed for thrombus control and procedural efficiency and versatility
- BOBBY™ Balloon Guide Catheter – Reliable flow arrest with streamlined preparation, optimized compatibility and next-generation balloon technology
- WEDGE™ Microcatheter – A navigation aid that minimizes ledge effect
- HEADWAY™ Microcatheters – Low-profile outer diameter, providing versatility, reliability, and fast access
- TRAXCESS™ Guidewires – Soft-tip design for challenging anatomies
About Terumo Neuro (Formerly MicroVention, Inc.)
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neurovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+1 714 206 9800
christine.mccullough@terumoneuro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/expanding-a-stroke-legacy-terumo-neuro-announces-us-commercial-availability-of-the-sofia-88-neurovascular-support-catheter-302453832.html
SOURCE Terumo Neuro